Prof Dr med Hanns-Peter Knaebel has moved between the operating table, industry, and hospital leadership in his career a path that now shapes his approach to one of the more ambitious experiments in German healthcare: merging two university hospitals into a single network. As CEO of the newly formed Heidelberg-Mannheim University Medicine Network, he's confronting the fragmentation long built into Germany's hospital system, and making the case that data, technology, and a new organisational model can free up clinical capacity without compromising care. Dr Knaebel also touches on the logic behind the merger, what Germany can learn from Spain, and his vision for a self-learning hospital network.
You have trained as a surgeon, spent time in industry, and worked across different geographies. Can you walk us through your journey and how you draw on it today?
Curiosity has probably been the defining theme. Moving back and forth between clinical medicine and industry teaches you that neither side has a monopoly on innovation – it is really about how you collaborate to take innovation to where it truly matters, which is the patient, and at scale.
Medicine socialises you in the one-to-one relationship between patient and caregiver. You genuinely understand individual clinical need, the patient journey, and the consequences of failure. Industry, by contrast, teaches you how to turn an idea into something reproducible within a regulatory framework – a scalable solution that reaches not one patient but many. If you remain only on one side, you risk underestimating the complexity of the system, and what it takes from either side to contribute to a successful therapy. And then, of course, there is the payer dimension – understanding the governmental and regulatory framework is equally indispensable.
Joseph Schumpeter, the Austrian economist, put it well: if it remains only an invention, it is not yet an innovation. To be an innovation, you must reach patients and the market at scale. None of us can transform healthcare alone. We have to do it together.
This is quite a new role, starting this year. Can you explain what brought you back to Germany and what this new institute actually is?
What drew me back was not the prospect of hospital management in the conventional sense. This is a once-in-a-generation opportunity to build a completely new model of university medicine – and that is the only lens through which I think about it. On paper, it is a merger between two university hospitals, but size alone is not quality. What size does provide is the potential to undergo a transformational process that smaller institutions simply could not undertake.
The discussion with the ministry began in March 2025. We were given three months of intensive conversations to explore whether my vision for the future aligned with theirs. In June, we made the decision to proceed. The opportunity is exceptional: Heidelberg and Mannheim have world-class clinical expertise across multiple fields, two medical faculties with outstanding research and education belonging to one university, and one of Europe’s strongest life science ecosystems – the German Cancer Research Centre, the European Molecular Biology Laboratory, the Max Planck Institute for Medical Research. This is not simply about merging two organisations. It is about creating an ecosystem that finally builds the bridge to what I call the fourth pillar: the translation of research and patient care into industry collaboration. I did not return to preserve an existing hospital system. I returned to build its next generation.
Any merger comes with significant challenges – culture, data, people, process. What has been your approach in these first months?
The strongest focus I have brought to this is the patient journey. Medicine is organised in vertical competence units – and rightly so, because we need depth in surgery, cardiology, radiotherapy, paediatrics. But the patient journey runs horizontally across those vertical units. The question is not how we optimise our own individual activities, but how we create genuine added value along that horizontal path. In industry, you would call it a value stream. If we create real value, the patient improves and can potentially be healed.
There are also persistent misconceptions on both sides that need to be addressed. Clinicians often assume that when commercial thinking enters the room, it is profit without patient benefit. Industry frequently assumes that clinical adoption follows automatically once regulatory approval is secured – which it does not. And on both sides, a successful pilot project is often treated as successful innovation, which it is not. Correcting those perceptions is part of the foundational work.
Could this merger become a template for other regions in Germany?
It could become a reference model, but it will not be a blueprint that can simply be copied. Every region has its own institutional, political, and medical realities. What is potentially transferable is the underlying logic: complementary rather than redundant specialisation and duplication; shared enabling platforms across tertiary, secondary, and primary care; sufficient scale for data and technology investment; and an integrated ecosystem connecting research, care, and industry.
Our model is not about centralising everything. It is about creating two compatible units with additional partners in our network, combining the advantages of scale with the strengths and identities of both locations. We are not going to annihilate the identity of either organisation – we are going to blend those identities into a stronger shared future.
Doctors are already working at capacity. How do you create time and mental bandwidth for them to work differently?
You cannot improve performance by piling more responsibility onto a plate that is already full. The question is: what do I take off the plate in order to liberate capacity for the human touch and the high-level patient care that only a clinician can provide?
I was at one of Europe’s largest software companies just this morning, and we heard a presentation on how much time is wasted, how many clicks are required to document a patient or write a discharge letter. The question our digital transformation must answer is: how do we liberate that time? I am completely opposed to the statement that technology will dehumanise medical care. I believe the opposite is true. We need to utilise technology to allow more human touch, more time for genuine patient interaction. Data and technology are probably the key to achieving that.
You have worked in Saudi Arabia – a very different financial environment. How constrained are you in comparison in Germany, and how are you approaching the funding challenge?
I would make the perhaps daring statement that there is practically no healthcare system that does not have financial constraints. That puts the responsibility on us to improve our effectiveness first, and then our efficiency. I want to stress that distinction: efficiency without effectiveness is not a value – it needs to come with improved performance, not merely reduced cost.
We need to generate financial headroom to make the necessary investments, but those investments are practically unavoidable. If we want to be one of Europe’s leading university healthcare networks, we must operate at the forefront of medical innovation and technology. We have some support from the state government, and beyond that we must look to ourselves – but that comparison holds against many other players in the world.
Spain has become Europe’s leading country for clinical trials despite having a smaller economy than Germany. How are you drawing inspiration from these international exemplars?
No country, however developed, has a monopoly on doing everything right – not Germany, not Saudi Arabia, not Spain. But Spain achieves remarkable treatment outcomes with significantly fewer resources, and that is impressive. What they have done particularly well is develop strong regional care models with a genuine emphasis on primary care, running coordinated patient pathways that do not think in sectors between inpatient and outpatient care.
As a side note, that sectoral thinking is entirely illogical from the patient’s perspective – a patient does not get up in the morning and decide whether today they are an inpatient or an outpatient. Spain thinks along the entire value stream: prevention, primary care, specialist treatment, follow-up. In Germany, by contrast, we invest considerable resources but remain highly fragmented between inpatient and outpatient care, with different payers, different providers, and numerous digital systems that are not interoperable. Germany does not have a resource problem – it has a coordination problem, and a lack of coordination is a productivity problem. There is still a lot of air in the system that needs to be deflated.
There are concerns in Germany about access to innovation, pricing reform, and the country’s status as an early-launch market. How worried are you?
We all need to change – caregivers, hospitals, outpatient settings, industry. Everyone must deliver their share. What I think we are missing, and should not be missing, is a medical target picture: a defined vision of how we want to treat our population. We know the disease burden. We know the incidence and prevalence of diseases by region. We know what transfer times for certain conditions should look like. We have all the information needed to develop a target picture for how we want to deliver care at every level, and what resources we need to deploy.
The mistake we are making is that the system is under financial pressure – understood and agreed – but decisions are being made purely on a cost basis, not on the basis of a medical target picture. That is the clear miss from policymakers. I understand the sense of urgency. But it is starting at the wrong end.
Germany is strong in basic research, but the translation of that research into products and clinical use has historically been a weak point. What is your approach to bridging that gap?
The failure to bring innovation to scale is rarely at the point of invention. The research piece is excellent – in Germany and elsewhere. The failure occurs in the space between clinical evidence and adoption. Researchers are rewarded for publications. Hospitals are rewarded for delivering care within operational constraints. Start-ups are rewarded for reaching the next financing round. Payers are rewarded for controlling short-term expenditure. No single actor is accountable for successful translation across the entire pathway, because everyone is running on different incentives. When incentives are misaligned, it is very difficult to point people in the same direction.
What we need – and what I believe we can now build – is an end-to-end innovation pathway. We have world-class discovery in Heidelberg, strong application orientation and medtech capabilities in Mannheim, outstanding partners in Heidelberg University, the German Cancer Research Centre, European Molecular Biology Laboratory, and others. The dots themselves are world class. Our task now is to connect them. From scientific discovery to clinical validation to industrial development. It is, in a sense, paint by numbers. The components are there. The work is to join them up and the Heidelberg-Mannheim Health + Life Science Alliance is a great starting point.
What would you like the international pharmaceutical industry to think of when they hear about this new institution?
Three things. First, we are unequivocally about medical excellence and innovation – that is a firm commitment from this institution and from the broader ecosystem around it. Second, we are fully committed to being a data-driven university medicine network, because what industry is specifically lacking right now is not synthesised or artificial data sets, but real-world clinical data. That is what they want, and that is what we intend to provide access to. Third, we are committed to the full translation journey – from invention, through clinical validation, to patient impact. Those are not aspirations. They are the things we are building towards, connecting world-class components that already exist here.
If we return in three to four years, what milestones will tell you that you have achieved what you set out to do?
First, a clear governance and cooperation model for the entire ecosystem – not only for our hospital university network, but for all the players around it. Everyone wants this, but we are still somehow lacking it. A governance framework that gives us the liberty to move quickly on further developments is the prerequisite for everything else.
Second, you should be able to report that we are a genuinely data-driven university hospital network – visible, amongst others, in oncology, in cardiovascular medicine, in surgery, where we are operating robotic operating rooms at meaningful scale.
Third – and this is perhaps the most personally important – the data-driven approach is, for me, the pathway into a learning university medicine system. One that systematically uses the information and data it generates to continuously improve patient care. We currently focus heavily on individual excellence, and we have a great deal of it. But when someone retires, sometimes the wheel gets reinvented. Organisational learning, fuelled by data, should prevent that. We are not lacking data. We are lacking the accessibility and interoperability of data at the point of care and the point of decision making. That is what we are going to change.

